Liraglutide Research
Liraglutide in mild to moderate Alzheimer disease: a phase 2b clinical trial
Nature Medicine·January 1, 2026
Paul Edison, et al.
Summary
GLP-1 receptor agonist liraglutide in Alzheimer disease. Part of ongoing research into metabolic-neurodegenerative connections.
Study Details
Study Design
Phase 2b randomized, double-blind, placebo-controlled trial (ELAD)
Indication
Mild to moderate Alzheimer disease
Intervention
Liraglutide vs placebo
Species
Human